Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Nathan Singh"'
Autor:
Ajay Major, Jovian Yu, Navika D. Shukla, Rachel Treitman, Manali K. Kamdar, Bradley M. Haverkos, James Godfrey, Melissa A. Babcook, Timothy J. Voorhees, Sophie G Carlson, Daria Gaut, Caspian Oliai, Jason T. Romancik, Allison Winter, Brian T. Hill, Radhika Bansal, Jose C. Villasboas, Imran A. Nizamuddin, Reem Karmali, Lindsey A. Fitzgerald, Deborah M. Stephens, Priyanka A. Pophali, Asaad Trabolsi, Jonathan H. Schatz, Marie Hu, Veronika Bachanova, Michael J Slade, Nathan Singh, Nausheen Ahmed, Joseph P. McGuirk, Michael R. Bishop, Peter A. Riedell, Justin Kline
Publikováno v:
Blood. 140:1328-1331
Autor:
Armin Ghobadi, Jack H. Landmann, Alun Carter, Matthew L. Cooper, Mehmet Emrah Selli, Jufang Chang, Matthew Baker, Christopher A. Miller, Francesca Ferraro, David Y. Chen, Amanda M. Smith, Taylor A. LaValle, Eric J. Duncavage, Justin Chou, Victor Tam, Joseph M. Benoun, Jenny Nater, Nathalie Scholler, Francesca Milletti, Remus Vezan, Adrian Bot, John M. Rossi, Nathan Singh
Publikováno v:
Blood Advances. 6:5634-5640
Autor:
Alexander B. Kim, Ssu-Yu Chou, Solomon Kang, Eric Kwon, Matthew Inkman, Jeffrey Szymanski, Neal Andruska, Cian Colgan, Jin Zhang, Joanna C Yang, Nathan Singh, Carl DeSelm
Publikováno v:
Blood Advances.
CAR T-cell therapy represents a major advance for hematologic malignancies, with some patients achieving long-term remission. However, the majority of treated patients still die of their disease. A consistent predictor of response is tumor quantity,
Autor:
Ajay Major, Jovian Yu, Navika Shukla, Yan Che, Theodore G Karrison, Rachel Treitman, Manali Kamdar, Bradley M Haverkos, James Godfrey, Melissa A Babcook, Timothy J Voorhees, Sophie Gabrielle Carlson, Daria Gaut, Caspian Oliai, Jason T. Romancik, Allison M Winter, Brian T. Hill, Radhika Bansal, Jose Caetano Villasboas, Imran A. Nizamuddin, Reem Karmali, Lindsey A. Fitzgerald, Deborah M. Stephens, Priyanka A Pophali, Asaad Trabolsi, Jonathan H Schatz, Marie Hu, Veronika Bachanova, Michael Slade, Nathan Singh, Nausheen Ahmed, Joseph P McGuirk, Michael R. Bishop, Peter A. Riedell, Justin Kline
Publikováno v:
Blood Advances.
Checkpoint inhibitor (CPI) therapy with anti-PD-1 antibodies has been associated with mixed outcomes in small cohorts of aggressive B-cell lymphoma patients following CAR T-cell therapy failure. To more definitively define CPI therapy efficacy in thi
Autor:
Nathan, Singh
Publikováno v:
Hematology Am Soc Hematol Educ Program
Immunotherapy is now a well-established modality in the treatment of cancer. Although several platforms to redirect the immune response exist, the use of genetically modified T cells has garnered particular attention in recent years. This is due, in
Autor:
Mehmet Emrah Selli, Jack Landmann, John Lattin, Amanda Heard, John Warrington, Helen Ha, Jufang Chang, Natalie Kingston, Graham Hogg, Mark Foster, Samantha Kersting-Schadek, Marina Terekhova, David DeNardo, Todd A. Fehniger, Maxim Artyomov, Nathan Singh
Publikováno v:
Blood. 140:2354-2355
Autor:
Katharina E. Hayer, Balraj Doray, Marco Ruella, Amanda Heard, Jufang Chang, Matthew D. Weitzman, Saar Gill, John Lattin, Nathan Singh, Regina Fluhrer, Jack Landmann, Mehmet Emrah Selli, Helen Ha, Abby M. Green
Publikováno v:
Blood. 138:1721-1721
Chimeric antigen receptor-engineered T cells targeting CD19 (CART19) have revolutionized the management of relapsed and refractory B cell malignancies. Despite high initial response rates, many patients with acute lymphoblastic leukemia (ALL) ultimat
Autor:
David A. Christian, David M. Barrett, Amy Shyu, Saar Gill, Jessica Perazzelli, Pranali Ravikumar, Mohamed Abdel-Mohsen, Noelle V. Frey, Janis K. Burkhardt, Boris Engels, Brian Granda, Marco Ruella, Melissa Ramones, Jennifer Brogdon, Stephan A. Grupp, Linlin Zhao, Nathan Singh, Steven L. Highfill, Florent Colomb, Regina M. Young, Shannon L. Maude, Liaomin Peng, Xeuqing Maggie Lu, Olga Shestova, Nathan H. Roy, Simon F. Lacey, Carl H. June
Publikováno v:
Blood. 134:247-247
We recently conducted a clinical trial of CD22-directed chimeric antigen receptor (CAR) T cells in children and adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). While we did observe some transient responses, overall outco
Autor:
Ophir Shalem, Katharina E. Hayer, Albert Hong, Atushi Hoshino, Matthew D. Weitzman, Olga Shestova, Saar Gill, Carl H. June, Nathan Singh, Marco Ruella, Pranali Ravikumar
Publikováno v:
Blood. 132:698-698
Background: T cells engineered to express chimeric antigen receptors targeting the B-cell antigen CD19 (CART19) have demonstrated impressive results in the treatment of lymphoid cancers. Despite these promising outcomes, a significant subset of patie
Autor:
Stephan A. Grupp, Boris Engels, Dana Haagen, Saar Gill, Olga Shestova, Simon F. Lacey, David L. Porter, Noelle V. Frey, David M. Barrett, Regina M. Young, Katherine T. Marcucci, Jennifer Brogdon, J. Joseph Melenhorst, Carl H. June, Shannon L. Maude, David A. Christian, Marco Ruella, Jessica Perazzelli, Nathan Singh
Publikováno v:
Blood. 130:807-807
Introduction. Anti-CD19 chimeric antigen receptor T cells (CART19 or CTL019) have shown impressive clinical activity in B-cell acute lymphoblastic leukemia (B-ALL) and are poised to receive FDA approval. However, some patients relapse after losing CD